Gasbarrini A, Lauritano E C, Garcovich M, Sparano L, Gasbarrini G
Internal Medicine Department, Gemelli Hospital, Catholic University of Sacred Heart, Rome, Italy.
Eur Rev Med Pharmacol Sci. 2008 Aug;12 Suppl 1:111-7.
Irritable bowel syndrome (IBS) is a complex disorder clinically characterized by abdominal pain and altered bowel habit. Its pathogenetic mechanisms are still incompletely known; genes, psychosocial factors, changes in gastrointestinal motility and visceral hypersensitivity are traditionally thought to play a crucial role in symptom generation. Recent studies have identified new additional factors that can interact with the established mechanisms. Dysregulation of brain-gut axis, gastrointestinal infection, low-grade infiltration and activation of mast cells in the intestinal mucosa with consequent release of bioactive substances, and altered serotonin metabolism are the emerging factors of IBS pathogenesis. Finally, modification of small bowel and colonic microflora and altered gas balance may be of relevance in at least some subgroups of IBS patients. New therapies can be developed only on the basis of a better understanding of the heterogeneous picture of the pathophysiology of IBS.
肠易激综合征(IBS)是一种复杂的疾病,临床特征为腹痛和排便习惯改变。其发病机制仍不完全清楚;传统上认为基因、心理社会因素、胃肠动力变化和内脏超敏反应在症状产生中起关键作用。最近的研究发现了一些新的额外因素,这些因素可与既定机制相互作用。脑-肠轴失调、胃肠道感染、肠黏膜中肥大细胞的低度浸润和激活以及随之而来的生物活性物质释放,以及血清素代谢改变是IBS发病机制中的新出现因素。最后,小肠和结肠微生物群的改变以及气体平衡的改变可能至少在部分IBS患者亚组中具有相关性。只有在更好地理解IBS病理生理学的异质性情况的基础上,才能开发新的治疗方法。